GlassScriptPhysician profile
Elbert Alan Duncan
NPI 1720020795
$5,713.38
in general payments reported to CMS, 2019-2025
37 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $170 · 2021: $562 · 2022: $1,131 · 2023: $1,093 · 2024: $1,272 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $763.37 | 2019-2025 | Xtandi, Padcev |
| Dendreon Pharmaceuticals LLC | $741.33 | 2021-2025 | Provenge |
| Janssen Biotech, INC. | $713.05 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $471.41 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $395.34 | 2019-2025 | |
| Eisai INC. | $290.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $234.73 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Bioprotect Medical, INC. | $210.08 | 2024-2025 | Bioprotect Balloon Implant System |
| Novartis Pharmaceuticals Corporation | $205.98 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $188.26 | 2023-2025 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $176.41 | 2019-2024 | Opdivo |
| Genzyme Corporation | $168.20 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $144.14 | 2022-2025 | Lynparza |
| Tolmar, INC. | $112.09 | 2023-2025 | Eligard, Rubraca, Jatenzo |
| Blue Earth Diagnostics | $111.16 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $93.55 | 2023 | Yonsa, Odomzo |
| Myriad Genetic Laboratories, INC. | $71.74 | 2021-2025 | Myrisk |
| Telix Pharmaceuticals | $66.83 | 2024-2025 | Illuccix |
| Boston Scientific Corporation | $66.04 | 2021-2024 | Spaceoar Vue System - 10ml |
| Seagen INC. | $48.87 | 2022-2023 | Padcev |
| Pharmaand Gmbh | $48.51 | 2025 | Rubraca |
| Myovant Sciences INC. | $45.73 | 2021-2022 | |
| Palette Life Sciences, INC. | $42.23 | 2023 | |
| Aveo Pharmaceuticals, INC. | $40.34 | 2022-2023 | Fotivda |
| Progenics Pharmaceuticals, INC. | $35.58 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $32.41 | 2019 | |
| Amgen INC. | $27.82 | 2020-2021 | |
| Teleflex LLC | $21.47 | 2025 | Barrigel |
| Mim Software INC. | $21.00 | 2024 | Maestro |
| Tolmar Pharmaceuticals, INC. | $18.76 | 2022 | |
| Coherus Oncology, INC. | $17.69 | 2022 | |
| Emd Serono, INC. | $17.68 | 2023 | Bavencio |
| Medtronic, INC. | $17.48 | 2021 | |
| Bard Peripheral Vascular, INC. | $13.83 | 2023 | Model 200 Theraseed Palladium-103 In Readylink |
| Axonics, INC. | $13.75 | 2023 | Axonics |
| Lilly USA, LLC | $12.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elbert Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.